Search Results - dimitrov

11 Results

Sort By:

Fully Human Antibodies and Antibody Drug Conjugates Targeting CD276 (B7-H3) for the Treatment of Cancer

Abstract: Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis occurs during normal growth and development, where it is known as physiological angiogenesis, and during the growth of solid tumors, where it is known as pathological angiogenesis. CD276, also known as B7-H3, is a cell surface tumor endothelial...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Steven Seaman, Saurabh Saha, Xaioyan Zhang, Dean Welsch, Gary Decrescenzo

Keywords(s): Antibody Drug Conjugate (ADC), B7-H3, CANCER, CD276, Dimitrov, immuno-oncology, Immunotherapy, Monoclonal Antibody

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Human and Improved Murine Monoclonal Antibodies Against CD22

Abstract: CD22 is a common cell surface glycoprotein expressed in B-cells and present in B-cell lymphomas; e.g., hairy cell leukemia (HCL), non-Hodgkins lymphoma (NHL), chronic lymphoblastic leukemia (CLL), and other cancers. It is therefore a target for cancer immunotherapy. Conjugation of anti-CD22 monoclonal antibodies with toxins or drugs has shown...

Published: 8/14/2024 | Inventor(s): Dimiter Dimitrov, Xiaodong Xiao, Ira Pastan

Keywords(s): antibodies, ANTIGEN, B-CELL, B-Cell Lymphoma, Bcl, CANCER, CD22, Chronic Lymphoblastic Leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Human, monoclonal, NHL, non-Hodgkins lymphoma, Oncology

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Human Monoclonal Antibodies Cross-reacting to Insulin-like Growth Factors IGF-I and IGF-II as Potential Anti-tumor Agents

Abstract: The National Cancer Institute's Cancer and Inflammation Program is seeking statements of capability or interest from parties interested in licensing this technology. The type 1 insulin-like growth factor (IGF) receptor (IGF1R) is over-expressed by many tumors and mediates proliferation, motility, and protection from apoptosis. Agents that...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Qi Zhao, Zhongyu Zhu

Keywords(s): Dimitrov, IGF-I, IGF-II, insulin-like growth factor, Monoclonal Antibody

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Single domain CD4, HIV-1 Antibodies, and Fusion Proteins for treatment of HIV

Abstract: Soluble forms of human CD4 (sCD4) inhibit HIV-1 entry into immune cells. Different forms of sCD4 and their fusion proteins have been extensively studied in animal models and clinical trials as promising HIV-1 inhibitors. However, they have not been successful in clinical trials due to their transient efficacy. sCD4 is also known to interact...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Weizhao Chen

Keywords(s): CD4, Dimitrov, fusion protein, HIV-1, Single Domain Antibodies (sdAb)

Category(s): Application > Therapeutics, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing

Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers

Abstract: Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic. Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR. Thus,...

Published: 4/8/2024 | Inventor(s): Rimas Orentas, Nirali Shah, Ira Pastan, Crystal Mackall, Dimiter Dimitrov

Keywords(s): Acute Lymphoblastic Leukemia, adoptive cell therapy, ALL, B-CELL, CD22, Chimeric antigen receptors (CARs), Chronic lymphocytic leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Immunotherapy, pediatric

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Fusion Proteins as HIV-1 Entry Inhibitors

Abstract: Soluble forms of human CD4 (sCD4) inhibit HIV-1 entry into immune cells. Different forms of sCD4 and their fusion proteins have been extensively studied as promising HIV-1 inhibitors – including in animal models and clinical trials. However, they have not been successful in human studies due to their transient efficacy. sCD4 is also known...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Weizhao Chen, Tianlei Ying

Keywords(s): antibody dependent cellular cytotoxicity (ADCC), Class II major histocompatibility complex (MHCII), Dimitrov, fusion protein, HIV-1, sCD4

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease

Monoclonal Antibody Fragments for Targeting Therapeutics to Growth Plate Cartilage

Abstract: A child's growth is dependent on the proper functioning of the growth plate, a specialized cartilage structure located at the ends of long bones and within the vertebrae. The primary function of the growth plate is to generate new cartilage, which is then converted into bone tissue and results in the lengthening of bones. Failure of the growth...

Published: 4/8/2024 | Inventor(s): Jeffrey Baron, Sao Fong (Crystal) Cheung, Chun Lui, Dimiter Dimitrov, Zhongyu Zhu

Keywords(s): Anti-mantrilin-3 Antibody, ARTHRITIS, Baron, Cartilage, Dimitrov, Eunice Kennedy Shriver National Institute on Child Health an, Growth plate, Human Growth Hormone, monoclonal, NICHD, OSTEOARTHRITIS, Short Stature, Skeletal Dysplasia

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Novel Fusion Proteins for HIV Vaccine

Abstract: Development of successful HIV vaccine immunogens continues to be a major challenge. Although gp120 was identified as having significant potential as a vaccine immunogen, attempts to elicit broadly neutralizing antibodies using recombinant gp120 failed. The highly flexible gp120 may present numerous conformations to the humoral immune system...

Published: 7/25/2024 | Inventor(s): Dimiter Dimitrov, Weizhao Chen

Keywords(s): ANTIBODY, CD4, Dimitrov, fusion protein, gp120, HIV Vaccine

Category(s): TherapeuticArea > Immunology, Application > Research Materials, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing

Her2 Monoclonal Antibodies, Antibody Drug Conjugates as Cancer Therapeutics

Abstract: Antibody drug conjugates (ADC) can demonstrate high efficacy as cancer therapeutics, however, much more can be done to improve their efficacy and safety profile. Site-specific antibody drug conjugation is a promising way to do this. Scientists at the NCI’s Laboratory of Experimental Immunology have identified a fully human monoclonal antibody,...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Zhongyu Zhu, Pradman Qasba, Boopathy Ramakrishnan

Keywords(s): ADC, antibody drug conjugate, Dimitrov, HER2, Her2 positive, Her2-overexpression

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Human Antibody for Deploying CH2-Based Therapeutics

Abstract: The National Cancer Institute seeks parties to license fully human antibodies for CH2-based research materials. Recently, isolated immunoglobulin constant CH2 domains were proposed as scaffolds for construction of libraries containing diverse binders that could confer some effector functions. As a fragment in all IgGs, which are at high concentrations...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Rui Gong

Keywords(s): CH2, conformational epitope, Dimitrov, effector functions, IgG

Category(s): Application > Research Materials, Collaboration Sought > Licensing, TherapeuticArea > Oncology

1 2